Breast cancer is one of the most common malignancies in women. Patient-derived tumor xenograft (PDX) model is a cutting-edge approach for drug research on breast cancer. However, PDX still exhibits differences from original human tumors, thereby challenging the molecular understanding of tumorigenesis. In particular, gene expression changes after tissues are transplanted from human to mouse model. In this study, we propose a novel computational method by incorporating several machine learning algorithms, including Monte Carlo feature selection (MCFS), random forest (RF), and rough set-based rule learning, to identify genes with significant expression differences between PDX and original human tumors. First, 831 breast tumors, including 657 ...
The development of therapies that target specific disease subtypes has dramatically improved outcome...
<div><p>Identification of novel cancer genes for molecular therapy and diagnosis is a current focus ...
Identification of novel cancer genes for molecular therapy and diagnosis is a current focus of breas...
Breast cancer is one of the most common malignancies in women. Patient-derived tumor xenograft (PDX)...
International audienceABSTRACT: INTRODUCTION: Identification of new therapeutic agents for breast ca...
Patient-derived xenograft (PDX) tumor model is a powerful technology in evaluating anti-cancer drugs...
(1) Background: Inter-tumour heterogeneity is one of cancer’s most fundamental features. Patient str...
In silico models to predict which tumors will respond to a given drug are necessary for Precision On...
Patient-derived xenograft (PDX) tumor model is a powerful technology in evaluating anti-cancer drugs...
Patient-derived tumor xenograft (PDX) mouse models are widely used for drug screening. The underlyin...
Acute lymphoblastic leukemia is a hematological malignancy that gains a proliferative advantage and ...
Introduction: Identification of new therapeutic agents for breast cancer (BC) requires preclinical m...
In developed countries, breast cancer is the commonest malignancy among women. Understanding the mec...
Background - Patient-Derived Tumour Xenografts (PDTXs) have emerged as the pre-clinical models that ...
Abstract Background Transgenic mouse tumor models have the advantage of facilitating controlled in v...
The development of therapies that target specific disease subtypes has dramatically improved outcome...
<div><p>Identification of novel cancer genes for molecular therapy and diagnosis is a current focus ...
Identification of novel cancer genes for molecular therapy and diagnosis is a current focus of breas...
Breast cancer is one of the most common malignancies in women. Patient-derived tumor xenograft (PDX)...
International audienceABSTRACT: INTRODUCTION: Identification of new therapeutic agents for breast ca...
Patient-derived xenograft (PDX) tumor model is a powerful technology in evaluating anti-cancer drugs...
(1) Background: Inter-tumour heterogeneity is one of cancer’s most fundamental features. Patient str...
In silico models to predict which tumors will respond to a given drug are necessary for Precision On...
Patient-derived xenograft (PDX) tumor model is a powerful technology in evaluating anti-cancer drugs...
Patient-derived tumor xenograft (PDX) mouse models are widely used for drug screening. The underlyin...
Acute lymphoblastic leukemia is a hematological malignancy that gains a proliferative advantage and ...
Introduction: Identification of new therapeutic agents for breast cancer (BC) requires preclinical m...
In developed countries, breast cancer is the commonest malignancy among women. Understanding the mec...
Background - Patient-Derived Tumour Xenografts (PDTXs) have emerged as the pre-clinical models that ...
Abstract Background Transgenic mouse tumor models have the advantage of facilitating controlled in v...
The development of therapies that target specific disease subtypes has dramatically improved outcome...
<div><p>Identification of novel cancer genes for molecular therapy and diagnosis is a current focus ...
Identification of novel cancer genes for molecular therapy and diagnosis is a current focus of breas...